Rashmi Mishra

Rashmi Mishra

Auto-generated profile, based on publicly available information

Rashmi Mishra

Department of Surgery, Washington University School of Medicine, Saint Louis, MO, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
RMRashmi Mishra
Rashmi Mishra
FAFoluso Ademuyiwa
Foluso Ademuyiwa
YYYilin Yang
Yilin Yang
JHJohn Herndon
John Herndon
LLLijin Li
Lijin Li
WGWilliam E. Gillanders
William E. Gillanders
Tumor-associated antigen (TAA) vaccines are being explored as a strategy to induce antitumor immune responses. Mammaglobin-A (Mam-A) is a TAA expressed in >50% of patients with breast cancer. Previously, we have shown that Mam-A DNA vaccines induce antitumor immune responses in patients with stable metastatic disease. To further evaluate the potential of the Mam-A vaccine, we initiated a phase Ib clinical trial in patients with estrogen receptor–positive breast cancer prior to surgery. Eight patients were assigned to arm 1 (neoadjuvant endocrine therapy alone) and 17 to arm 2 (neoadjuvant endocrine therapy plus Mam-A vaccination); the final analysis included 8 patients from arm 1 and 13 from arm 2. Ex vivo enzyme-linked immunospot (ELISpot) analysis of peripheral blood mononuclear cells demonstrated that Mam-A vaccination induced Mam-A–specific T cells in 8 of 13 patients. Intracellular cytokine staining and Mam-A–specific tetramer staining revealed that vaccine-induced Mam-A–specific T cells included both CD4+ and CD8+ polyfunctional T cells. Finally, high-throughput imaging mass cytometry identified 24 cellular metaclusters with features of tumor, immune, stromal, and endothelial cells and revealed an increased CD8+ T-cell prevalence in the tumor after Mam-A vaccination. In particular, vaccination was associated with the infiltration of PD-1+CD8+ T cells. In addition, postvaccination tumor samples exhibited close spatial interactions between cytotoxic CD8+ T cells (CTL) and Mam-A+ tumor cells and between CTL and antigen-experienced CD4+ T cells. Together, these results suggest that Mam-A DNA vaccination elicits both systemic and intratumoral antitumor immune responses.

4 September 2026 in Science Advances
Verified
Journal Article
Open access
FPFelicia Zhang Perkins
Felicia Zhang Perkins
XZXiuli Zhang
Xiuli Zhang
YYYik Yeung Lawrence Yu
Yik Yeung Lawrence Yu
YYYilin Yang
Yilin Yang
DCDarren Cullinan
Darren Cullinan
WGWilliam E. Gillanders
William E. Gillanders
Pancreatic ductal adenocarcinoma (PDAC) is unresponsive to standard immunotherapies despite harboring cancer neoantigens capable of eliciting T cell responses. We completed two phase 1 clinical trials (NCT03956056 and NCT03122106) evaluating safety and immunogenicity of synthetic long peptide (SLP) and DNA personalized cancer vaccines (PCVs). PCVs were administered after resection and adjuvant chemotherapy. Tumor/normal whole-exome sequencing, RNA sequencing, and pVACtools were used to identify and prioritize candidate PCV neoantigens. PCVs were well tolerated without any grade ≥3 adverse events. Neoantigen-specific responses were demonstrated by interferon-γ enzyme-linked immunospot and intracellular cytokine staining. Expanded T cell receptor clonotypes were sequenced and transduced into autologous peripheral blood mononuclear cells to confirm neoantigen specificity. When compared with a contemporaneous institutional propensity-matched cohort, PCV patients demonstrated a trend toward prolonged median overall survival (4.4 versus 3.5 years, log-rank P = 0.23). Overall, PDAC PCVs are safe and feasible and elicit polyclonal T cell responses, linking prioritized cancer neoantigens to functional antitumor immunity.

2 April 2026
Verified
Other
Open access
RMRashmi Mishra
Rashmi Mishra
FAFoluso Ademuyiwa
Foluso Ademuyiwa
YYYilin Yang
Yilin Yang
JHJohn Herndon
John Herndon
LLLijin Li
Lijin Li
WGWilliam E. Gillanders
William E. Gillanders
Tumor-associated antigen (TAA) vaccines are being explored as a strategy to induce antitumor immune responses. Mammaglobin-A (Mam-A) is a TAA expressed in >50% of patients with breast cancer. Previously, we have shown that Mam-A DNA vaccines induce antitumor immune responses in patients with stable metastatic disease. To further evaluate the potential of the Mam-A vaccine, we initiated a phase Ib clinical trial in patients with estrogen receptor–positive breast cancer prior to surgery. Eight patients were assigned to arm 1 (neoadjuvant endocrine therapy alone) and 17 to arm 2 (neoadjuvant endocrine therapy plus Mam-A vaccination); the final analysis included 8 patients from arm 1 and 13 from arm 2. Ex vivo enzyme-linked immunospot (ELISpot) analysis of peripheral blood mononuclear cells demonstrated that Mam-A vaccination induced Mam-A–specific T cells in 8 of 13 patients. Intracellular cytokine staining and Mam-A–specific tetramer staining revealed that vaccine-induced Mam-A–specific T cells included both CD4+ and CD8+ polyfunctional T cells. Finally, high-throughput imaging mass cytometry identified 24 cellular metaclusters with features of tumor, immune, stromal, and endothelial cells and revealed an increased CD8+ T-cell prevalence in the tumor after Mam-A vaccination. In particular, vaccination was associated with the infiltration of PD-1+CD8+ T cells. In addition, postvaccination tumor samples exhibited close spatial interactions between cytotoxic CD8+ T cells (CTL) and Mam-A+ tumor cells and between CTL and antigen-experienced CD4+ T cells. Together, these results suggest that Mam-A DNA vaccination elicits both systemic and intratumoral antitumor immune responses.

2 April 2026
Verified
Other
Open access
RMRashmi Mishra
Rashmi Mishra
FAFoluso Ademuyiwa
Foluso Ademuyiwa
YYYilin Yang
Yilin Yang
JHJohn Herndon
John Herndon
LLLijin Li
Lijin Li
WGWilliam E. Gillanders
William E. Gillanders
PBMCs recovered from ex vivo ELISpot were stimulated with 9-10mer Mam-A pulsed APCs overnight and stained for ICS and specific peptide-HLA tetramers